{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:38:57Z","timestamp":1767706737376,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.leukres.2024.107436","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:50:04Z","timestamp":1704775804000},"page":"107436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b"],"prefix":"10.1016","volume":"136","author":[{"given":"Ben K.","family":"Seon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Duzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew K.L.","family":"Goey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orla","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107436_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2024.107436_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B cell receptor signaling in lymphoid malignancies: new insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2024.107436_bib3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/343760a0","article-title":"Molecular components of the B-cell antigen receptor complex of the IgM class","volume":"343","author":"Hombach","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2024.107436_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/j.1460-2075.1990.tb08129.x","article-title":"B lymphocyte antigen receptors (mIg) are non-covalently associate with a disulfide linked, inducibly phosphorylated glycoprotein complex","volume":"9","author":"Campbell","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.leukres.2024.107436_bib5","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.str.2010.04.019","article-title":"Structural and functional studies of Ig\u03b1\u03b2 and its assembly with the B cell antigen receptor","volume":"18","author":"Radaev","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.leukres.2024.107436_bib6","doi-asserted-by":"crossref","first-page":"13468","DOI":"10.1073\/pnas.1907481116","article-title":"A symmetric geometry of transmembrane domains inside the B cell antigen receptor complex","volume":"116","author":"Gottwick","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2024.107436_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0161-5890(94)90061-2","article-title":"Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex","volume":"31","author":"Vasile","year":"1994","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.leukres.2024.107436_bib8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/intimm\/dxl072","article-title":"Identification of disulfide bonds in the Ig-\u03b1\/Ig-\u03b2 component of the B cell antigen receptor using the Drosophila S2 cell reconstitution system","volume":"18","author":"Siegers","year":"2006","journal-title":"Int. Immunol."},{"key":"10.1016\/j.leukres.2024.107436_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V81.1.84.84","article-title":"Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia\/non-Hodgkin\u2019s lymphoma and are effectively internalized after binding to the cell surface antigens","volume":"81","author":"Okazaki","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107436_bib10","series-title":"Leucocyte Typing V: White Cell Differentiation Antigens. Proceedings of the Fifth International Workshop and Conference (3-7 November, 1993, Boston, USA) Vol 1 (Edited by Schlossman SF et al.)","first-page":"667","article-title":"B23 CD79 workshop report","author":"Engel","year":"1995"},{"key":"10.1016\/j.leukres.2024.107436_bib11","first-page":"1966","article-title":"Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b)","volume":"10","author":"Zomas","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107436_bib12","first-page":"769","article-title":"Differential expresi\u00f3n of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukemia","volume":"10","author":"Astsaturov","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107436_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107436_bib14","unstructured":"FDA Approves Polatuzumab Vedotin-piiq for Diffuse Large B-cell Lymphoma| FDA. 6\/11\/2019. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121sooolbl.pdf\u3009."},{"key":"10.1016\/j.leukres.2024.107436_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107436_bib16","unstructured":"FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-cell Lymphoma, Not Otherwise Specified, and High-grade B-cell Lymphoma. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761121soo8lbl.pdf\u3009."},{"key":"10.1016\/j.leukres.2024.107436_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107436_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107436_bib19","first-page":"2721","article-title":"Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107436_bib20","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Review: immune checkpoint therapy \u2013 current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2024.107436_bib21","first-page":"850","article-title":"New monoclonal antibodies SN3, SN3a and SN3b directed to sialic acid of glycoprotein on human non-T leukemia cells","volume":"14","author":"Fukukawa","year":"1986","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2024.107436_bib22","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1073\/pnas.83.20.7898","article-title":"Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6","volume":"83","author":"Haruta","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2024.107436_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0145-2126(93)90154-D","article-title":"Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice","volume":"17","author":"Kawata","year":"1993","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2024.107436_bib24","first-page":"2688","volume":"54","author":"Kawata","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2024.107436_bib25","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1073\/pnas.84.10.3390","article-title":"Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models","volume":"84","author":"Hara","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2024.107436_bib26","first-page":"7846","article-title":"Antiangiogenic therapy of established tumors in human skin\/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide","volume":"61","author":"Takahashi","year":"2001","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2024.107436_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2024.107436_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.18341","article-title":"The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma","volume":"199","author":"Kawasaki","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107436_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/cancers14061453","article-title":"Review: DLBCL 1L \u2013 what to expect beyond R-CHOP?","volume":"14","author":"Stegemann","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.leukres.2024.107436_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1074-7613(00)00003-0","article-title":"Monomeric and oligomeric complexes of the B cell antigen receptor","volume":"13","author":"Schamel","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2024.107436_bib31","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ni1262","article-title":"The initiation of antigen-induced B cell antigen receptor signaling viewed in living cells by fluorescence resonance energy transfer","volume":"6","author":"Tolar","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.leukres.2024.107436_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.abo3923","article-title":"Cryo-EM structure of the human IgM B cell receptor","volume":"377","author":"Su","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.leukres.2024.107436_bib33","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.abo3828","article-title":"Cryo-EM structures of two human B cell receptor isotypes","volume":"377","author":"Ma","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.leukres.2024.107436_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.add8065","article-title":"Unveiling the B cell receptor structure","volume":"377","author":"Tolar","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.leukres.2024.107436_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101843","article-title":"Characterization of interactions within the Ig\u03b1\/Ig\u03b2 transmembrane domains of the human B-cell receptor provides insights into receptor assembly","volume":"298","author":"Lockey","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2024.107436_bib36","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1084\/jem.20161454","article-title":"Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM","volume":"214","author":"Wang","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2024.107436_bib37","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/2159-8290.CD-22-1401","article-title":"Targeting N-linked glycosylation for the therapy of aggressive lymphoma","volume":"13","author":"Scheich","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107436_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.leukres.2024.107436_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0163-7258(80)90058-3","article-title":"In vitro systems for evaluation of combination chemotherapy","volume":"8","author":"Momparler","year":"1980","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.leukres.2024.107436_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107436_bib41","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19","volume":"25","author":"Ormhoj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107436_bib42","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107436_bib43","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O`Learly","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107436_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107436_bib45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Views: overcoming antigen escape with CAR T-cell therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107436_bib46","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Mini review: tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107436_bib47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Review: fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107436_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2024.107436_bib49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1084\/jem.173.5.1053","article-title":"Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function","volume":"173","author":"Welsh","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2024.107436_bib50","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Investig."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262400002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262400002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:05:08Z","timestamp":1758935108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262400002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"alternative-id":["S014521262400002X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107436","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107436"}}